Acurx Pharmaceuticals, Inc.

NasdaqCM:ACXP 주식 보고서

시가총액: US$31.2m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Acurx Pharmaceuticals 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Dave Luci

최고 경영자

US$1.0m

총 보상

CEO 급여 비율46.4%
CEO 임기6.6yrs
CEO 소유권6.8%
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간3.2yrs

최근 관리 업데이트

Recent updates

Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely

Aug 11
Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release

Jan 22

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Oct 30
Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Jul 15
Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Mar 04
Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Nov 16
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering

Jul 25

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

May 13
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Jan 22
Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

Sep 30
Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers

Aug 27

CEO 보상 분석

Dave Luci 의 보수는 Acurx Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$1mUS$475k

-US$15m

Sep 30 2023n/an/a

-US$13m

Jun 30 2023n/an/a

-US$13m

Mar 31 2023n/an/a

-US$12m

Dec 31 2022US$655kUS$475k

-US$12m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$4mUS$364k

-US$13m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$596kUS$277k

-US$5m

Dec 31 2019US$290kUS$267k

-US$6m

보상 대 시장: Dave 의 총 보상 ($USD 1.02M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Dave 의 보상이 증가했습니다.


CEO

Dave Luci (57 yo)

6.6yrs

테뉴어

US$1,023,878

보상

Mr. David P. Luci, also known as Dave, CPA, J.D. Esq. served as Chairman of the Board at AMERI Holdings, Inc. since August 16, 2018 until December 12, 2018.Mr. Luci is the Co-Founder of Acurx Pharmaceutic...


이사회 구성원

이름위치테뉴어보상소유권
Robert DeLuccia
Co-Founder & Executive Chairman6.6yrsUS$1.06m5.94%
$ 1.9m
David Luci
Co-Founder6.6yrsUS$1.02m6.76%
$ 2.1m
Joseph Scodari
Independent Director3.2yrsUS$78.94k0.019%
$ 5.9k
Thomas Harrison
Independent Director3.2yrsUS$73.94k0.0095%
$ 3.0k
James Donohue
Independent Director3.2yrsUS$76.44k0.077%
$ 24.0k
Carl Sailer
Independent Director5.9yrsUS$66.44k0.72%
$ 225.7k
Jack Dean
Independent Director & Scientific Advisor3.2yrsUS$61.44k0.11%
$ 34.0k
Richard Ellison
Scientific Advisorno data데이터 없음데이터 없음
Ciaran Kelly
Scientific Advisorno data데이터 없음데이터 없음
Kevin Garey
Scientific Advisorno data데이터 없음데이터 없음
Mark Goldberger
Scientific Advisorno data데이터 없음데이터 없음
Ellie Goldstein
Scientific Advisorno data데이터 없음데이터 없음

3.2yrs

평균 재임 기간

71yo

평균 연령

경험이 풍부한 이사회: ACXP 의 이사회경험(평균 재직 기간 3 년)으로 간주됩니다.